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Summary Lung cancer is strictly associated with tobacco smoking. Tumours developed in non-smoking subjects account for less than 10%
of all lung cancers and show peculiar histopathlIogical features, being prevalentty adenocarcinomas. A number of genetic data suggest that
their biological behaviour may be different from that of lung tumours caused by smoking, howeverthe number of cases investigated to date is
too low to draw definitive conclusions. We have examined the status of p53 and K-rasgenes and the presence of loss ofheterozygosity (LOH)
at the FHIT locus in a series of 35 lung adenocarcinomas that developed in subjects who had never smoked. Results were compared with
those obtained in a series of 35 lung adenocarcinromas from heavy-smoking subjects. In the group of non-smoking subjects p53 mutations
and LOH at the FHIT locus were present in seven (20%) cases, and the two alterations were constantly associated (P < 0.0001), whereas
they were not related in the series of carcinomas caused bysmoking. In tumours developed in heavy-smoking subjects, thefrequency of LOH
at the FHIT locus was significantly higher (P = 0.006) than in tumours from non-smoking subjects. The frequency of p53 mutations in
adenocarcinomas caused by smoking was not different from that seen in non-smoking subjects. However, in the group of smoking subjects
we observed mostly G:C -* T:A transversions, whereas frameshift mutations and G:C -* A:T transitions were more frequently found in
tumours from non-smoking subjects. No point mutations of the K-ras gene at codon 12 were seen in subjects who had never smoked,
whereas they were present (mostly G:C -* T:A transversions) in 34% of tumours caused by smoking (P= 0.002). Our data suggest that lung
adenocarcinomas developed in subjects who had never smoked represent a distinct biological entity invoMng a co-alteration of the p53 gene
and the FHIT locus in 20% of cases.
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Lung cancer, the predominant cause of cancer-related death
throughout the world, is strictly related to tobacco smoking
(Shopland et al. 1991). A direct link between exposure to carcino-
gens contained in tobacco smoke and genetic abnormalities
involved in bronchial carcinogenesis is now emerging. Mutations
of p53. K-ras and FHIT genes are among the most frequent gene
alterations detected to date in lung cancer caused by smoking
(Rodenhuis and Slebos. 1988; Takahashi et al. 1989; Sozzi et al.
1996). The most common mutations found in p53 and K-ras genes
are G:C -* T:A transversions, a specific type ofmutation induced
by benzo(a)pyrene (B(a)P). one of the carcinogens present in
tobacco smoke (Suzuki et al. 1992: Slebos et al. 1991). Moreover.
it has been observed in vitro that B(a)P induces formations of
DNA adducts at the major mutational hotspots ofp53 (Denissenko
et al, 1996). The FHIT gene. located at chromosome 3pl4.2 and
containing the FRA3B fragile site. has recently been found
affected by somatic deletions in tumours caused by smoking
(Sozzi et al. 1996).
Tumours that developed in subjects who had never smoked
account for less than 10% of all lung cancers and show peculiar
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histopathological features, being predominantly adenocarcinomas
(Brownson et al. 1995). Genetic analyses conducted in small series
of lung carcinomas from subjects who had never smoked
suggest that their biological behaviour may be different from that
oflung cancercaused by smoking. In fact, it has been reported that
K-ras mutations in tumours from non-smoking subjects are rare
events (Slebos et al. 1991). and p53 mutations are less frequent
than in tumours developed in smoking subjects (Suzuki et al.
1992). Moreover. p53 mutations in a particular series of non-
smoking lung cancer from atomic-bomb survivors were mostly
G:C -e A:T transitions, thus suggesting that endogenous muta-
tional mechanisms could play a more relevant role in neoplasms of
non-smoking subjects (Takeshima et al, 1993). In addition, we
have recently observed that the frequency ofloss ofheterozygosity
(LOH) at microsatellite-containing loci located within the FHIT
locus was significantly lower in lung adenocarcinomas that
developed in subjects who had never smoked compared with
that observed in tumours from heavy-smoking subjects (Sozzi et
al. 1997). However, the number of non-smoking lung cancers
examined to date, especially for p53 and K-ras mutations, is
limited and only one gene has been investigated in each series
oftumours.
In the present study we have evaluated the status ofp53 and K-
ras genes. and the presence of LOH at the FHIT locus in a rela-
tively large number of lung adenocarcinomas from subjects who
had never smoked. Results were compared with those obtained in
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a corresponding series of lung adenocarcinomas from heavy-
smoking subjects. In the group ofsubjects who had never smoked
LOH at 3pl4.2 and p53 gene mutations were present in 20% of
cases and the two alterations were constantly associated On the
other hand, these two abnormalities were not related in the series
ofadenocarciomas caused by smoing used as control. The type
ofp53 mutations in tnuours from smoking subjects was different
from that observed in non-smoking subjects. No K-ras mutations
were observed in non-smoking tmnou, whereas in the group of
smoking subjects they were present in 34% of cases. Taken
together, the results suggest that lung adenocarcinomas that
developed in subjects who had never smoked represent a distinct
biological entity involving a coalteration of p53 gene and FHIT
locus in one-fifth ofcases.
MATERIALS AND METHODS
Patits and sampbs coietion
Thirty-five adenocarcinomas that developed in subjects who had
never smoked (5% of 708 cases of lung carcinomas undergoing
thoracic surgery at the Department of Surgery, University ofPisa,
during the 8-year period 1989-96) were analysed. Twenty-two of
these tumous were part of a series of 40 lung adenocarcinomas
from non-smoking subjects recently investigated for FHlT abnor-
malities (Sozzi et al, 1997); 13 additional cases were included in
the present study. Thirty-five consecutive cases oflung adenocarci-
nomas from patients with a history ofsmoking (>9 years and >10
cigarettes per day), collected during the period 1994-95, were also
analysed. All thse lung umours caused by smoking were different
from that used in the study by Sozzi et al (1997). In the group of
non-smoking subjects there were 29 (83%) women and six (17%)
men with amean age of58 years. Thirty-three (94%) ofthe patients
who smoked were men andtwo(6%) were women with amean age
of 62 years. Information about the exposition to environmental
tobacco smoke was carefully collected in all non-smoking patients.
In each case, tumour and normal lung tissue samples were snap-
frozen in liquid nitrogen within 10 min of excision and stored at
-800C. Immediately adjacent pieces of tumour tissue were fixed
and processed for diagnostic histopathology. Histological classifi-
cation was assessed using lightmicroscopy according tothe World
Health Organization criteria (World Health Organization, 1982).
All the tumours analysed were lung adenocarcinomas. Patient
stage at the time of diagnosis was based on the interational
staging system for lung tumours (Mountain 1986). In the non-
smoking group, 17 (49%) patients were classified at stage L, five
(14%) at stage II and 13 (37%) at stage Im. Among smoking
patients, 24 (69%) were at stage I, five (14%) at stage II and six
(17%) at stage HI (Tables 1 and 2). All patients received abdom-
inal CT scans to rule out the possibility of lung metastasis from
occult gastrointestina malignancy.
LOH at the FHIT locus
Tumour samples were dissected to eliminate normal tissue before
praratin of DNA. Genonic DNA was exracted friom frozen
tumours and matching ormal lung tissues using standard methods
(Blin and Stafford, 1976). Analysis of allelic losses of the FHIT
gene was performed by a polymerase chain reaction (PCR)-based
method. Primers thatamplifypolymorphicmicosatellite-containg
alleles were used for the following loci: D3S4103, D3S1300 and
D3S1234, all internal to the FHIT gene. Two additional microsatel-
lite markers, ACT`BP2 and MD located at chromosome 5 and 19,
respectively, were used in tunours fiom non-snmking subjects as
control for microsatellite instability. The sequences of all primers
can be obtained drugh the genome database. Routinely, 100 ng of
genomic DNA was amplified in a 10id PCR reaction containing
10mM Tris-HCl (pH 8.3), 1.5 mm magnesium chloride, 50mM
potassium chloride, 0.01% (w/v) gelatine, 1.25 mM each of four
dNTPs (Boehringer Mannheim Biochemica), 1 mM ofeach primer,
0.01 id of[a-32PJdCTP(3000CimmoHl,Amersham, Arlington, IL,
USA) and 0.1 units of Taq DNA polymrase (Perkin-Elmer Cetus,
Norwalk, CT, USA). The PCR reacion was programmed as
follows: initial denatration, 5 min at 94°C; amplfication, 30 s at
940C, 30 s at 57-60°C, 30 s at 70°C for 30 cycles. PCR products
were processed by the addition of5 Id ofloading buffer consisting
of 98% formamide, 1% EDTA (pH 8.0), 0.03% xylene cyanol and
0.03% bromophenol blue. The reaction was then denatwred at950C
for S min A 5-Id sample was loaded onto a 6% urea-polyacryl-
amide gel for 2-3 h at 55 W. The gels were dried and exposed
againstaKodak XAR-5 film at-80C. Forinformative cases, allelic
loss was scored if the autoradiographic signal of one allele was
reduced approximately 50% in the tumour DNAcompared with the
corrsponding normal allele by densitometric analysis using a GS-
670densitometerandtheMolecularAnalystDensitometry Software
(Bio-Rad, Bio-RadLaboratories, Herules, CA, USA).
p53 gene analysis
Genetic analysis of the p53 gene was performed using PCR-
single-strand conformation polymorphism (SSCP) to screen for
point mutations in exons 4-9, as described previously (Marchetti
et al, 1993), with the following modifications. Aftercompletion of
the PCR reaction, the product was diluted 1:5 in loading buffer
(95% formamide, 2 mm EDTA, pH 8.3). A 5-Id sample of the
diluted samples was denatured (5 min at 90°C), immediately
cooled on ice and loaded onto a non-denaturing 6% polyacryl-
amide gel. Electroporsis was carried out for 14 h at 200C at S W
in the presence of5% glycerol. Upon complete migration the gels
were dried and subjected toautoradiography. Direct sequencing of
the PCR products was performed with the same primers used for
amplification and the sequenase 2.0 Kit (United States
Biochemical).
K-ra gene analysis
The mutational analysis of codon 12 of the K-ras gene was
performed by oligodeoxynucleotide hybridization, as reported
previously (Marchetti et al, 1996). The primers used to amplify
the K-ras gene around codon 12 were: 5'-GGCCTGCTGA-
AAATGACTGA-3' and 5'- TGATTCTGAATTAGCTGTAT-3'.
The PCR reaction was programmed as follows: initial denatura-
tion, 4 min at 94°C; amplification, 30 s at 940C, 30 s at 540C,
1 min at 720C for 35 cycles; elongation, 10 min at 720C. The
amphfiedproducts ofthe PCRreaction were denatured andblotted
onto nylon membranes, which were then hybridized separately
with 32P-labelled mutation-specific oligonucleotideprobes.
Statstical analysis
The different variables of the analysed tmours were tested for
association using the chi-square and Fisher's exact tests using the
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Table 1 Genetic alterations and clinicopathoogicaI paameters in adenocarcinonas from non-smong subjects
Cases FHIT p53 K-ras T N Stage Passive
cmus gene gene smoking
39 - - T2 NO no
61 - - - T3 NO III yes
81 - - Ti NO no
88 - - Ti NO I no
89 - -- Ti Ni II yes
96 LOH Codon91:TGG(Trp)-*TAG(stop) - T3 N2 III no
i20 - - Ti NO I yes
127 LOH Intron5: deletion (-24 bps) - Ti N2 III yes
132 - - T2 N2 III no
222 -- T2 Ni II yes
233 LO- Codon242:TGC(Cys)-TTC(Phe) - Ti N2 III no
281 - - Ti NO yes
295 - - T2 N2 III yes
376 - - T2 N2 III yes
390 - - T2 NO yes
402 - - Ti N2 III no
404 - - T2 Ni II yes
421 LOH Codon 273: CGT (Arg) CT (framesift deletion) - T3 Ni III yes
442 LOH Codon 258: GAA (Glu) - AAA (Lys) - Ti Ni II yes
447 LOH Codon 131: CTC AAC AAG -* CTCAAG (deleton) - T2 NO yes
460 - - - T2 N2 III yes
466 - - - T2 NO yes
484 - - - T2 NO yes
488 - - - Ti N2 III yes
494 _- - T2 N2 III no
500 LOH Codon 248: CGG (Arg) CAG (Gin) - Ti NO yes
505 - - T2 NO no
508 - - Ti NO yes
509 - - T2 NO yes
510 - - T2 NO yes
540 - - T2 NO yes
559 - - Ti NO no
658 - - - T2 NO yes
697 - - T2 Ni II no
736 - - T2 N2 III yes
Statview 4.5 statistical software run on a PowerPC Macintosh
computer. A P-value of less than 0.05 was considered to have
statistical significance.
RESULTS
Thirty-five lung adenocarcinomas that developed in subjects who
had never smoked and 35 adenocarcinomas from heavy-smoking
subjects were analysed for LOH at the FHIT locus and forp53 and
K-ras gene abnormalities.
LOH at the FHIT locus
LOH at microsatellite-containing loci within the FH1T locus are
found to be stnctly associated with abnormal FH1T transcripts in
lung tumou (Sozzi et al, 1996), therefore loss of one FHIT allele
has been considered a crucial step leading to loss offumction of the
gene. Tumours and matched normal lung tissues were studied using
three nicrosatellite markers located within the FHIT gene. The
normal tissues of all samples were heterozygous for at least one of
these markers. Allelic losses affecting at least one locus were
present in 19 (54%) of the adenocarcinomas from heavy-smoking
subjects, whereas only seven (20%) of the tumours in the non-
smoking group showed LOH of the FH1T locus. This difference
was statistically significant (Fisher's exact text, P = 0.006). All of
the tumours showing loss ofone markeralso lost allofthe informa-
tive markers, suggesting a complete loss of one allele of the FHIT
gene. The results are displayed graphically in Figure 1. Two addi-
tional polymorphic microsatellite-containing loci (AC-TBP2 at
chromosome 5 and MD at chromosome 19) were analysed in
tumours from non-smoking subjects. In two cases (no. 61 and no.
120) a microsatellite instability was observed.
p53
A SSCP assay was performed on tumour-derived genomic DNA
and corresponding normal lung tissues to cover exons 4-9 ofp53.
PCR was repeated at least twice for each sample and only the
reproducible cases were taken. Bands of mobility shift were
sequenced to identify the mutations and exclude known polymor-
phisms. Seven (20%) of adenocarcinomas from never-smoking
subjects and eight (23%) of adenocarcinomas caused by smoking
showed p53 mutations. In non-smoking tumiours three ofthe seven
genomic alterations of the p53 gene were G:C-4A:T transitions,
three were deletions and one was a G:C-*T:A transversion (Table
1). In the group of smoking subjects five of the eight mutations
were G:C-*T:A transversions, two were A:T-*G:C transitions and
one was a single-base insertion (Table 2).
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K-ras
Point mutations at codon 12 ofthe K-ras gene were observed in 12
(34%) of the 35 adenocarcinomas developed in heavy-smoking
subjects. In the 12 tumours with mutated ras, the normal DNA
sequence GGT (glycine) at codon 12 was altered to TGT
(cysteine) in six cases (50%). to GTT (valine) in four cases (33%)
and to GAT (aspartic acid) in two cases (17%) (Table 2). In
tumours developed in non-smoking subjects no mutations at codon
12 of the K-ras gene were observed. The different distribution of
ras mutations in smoking subjects and non-smoking subjects was
statistically significant (Fisher's exact test, P = 0.002).
Associations between genetic alterations and
corelations with clinicopathological features
In tumours from non-smoking subjects, LOH affecting microsatel-
lite markers within the FH1T gene and p53 gene mutations were
constantly associated (seven cases, see Table 1) (Fisher's exact
test, P < 0.0001). Conversely, of the eight adenocarcinomas from
smoking subjects having a mutated p53 gene, six (75%) did not
show microsatellite alterations within the FHlT locus (Table 2).
This difference was statistically significant (Fisher's exact test,
P = 0.007). p53 and K-ras mutations in tumours from smoking
subjects were not associated, with only one exception. In the group
ofsmoking subjects, p53 mutations were significantly linked with
metastatic involvement of thoracic lymph nodes and late-stage
disease (contingency table, P = 0.0182 and P = 0.0165 respec-
tively). A trend was noted towards association between p53 muta-
tions and metastatic spread in the series of tumours from
non-smoking subjects, but the data were not significant. No corre-
lations were found between LOH at the FHIT locus or K-ras gene
alterations and clinicopathological data in lung tumours from
smoking subjects.
DISCUSSION
The genomic status of p53 and K-ras genes, and the presence of
LOH at the FHlT locus have been investigated in a series of lung
adenocarinomas thatdeveloped in subjects whohad neversmoked.
Deletions at chromosomal region 3pl4.2 and p53 abnormalities
were present in 20% of cases and the alterations were constantly
associated. Point mutations of the K-ras gene were never observed
in this series of lung adenocarcinomas. In lung tmours from
smoking subjects the frequency of LOH at the FH1T locus was
significantly higher, in agreement with previous results (Sozzi et al,
1997), suggesting that FHIT may be a specific molecular target of
cacinogens present in tobacco smoke. The frequency ofp53 muta-
tions in smoking adenocarcinomas was similar to that previously
reported by other groups in this particular histotype of lung cancer
Table 2 Genetic alterations and dinicopathobgical parameters in adenocarcinomas from heavy-smoking subjects
cases FHIT p53 K-ras T N Stage
kxus gene gene
1 GAT T2 NO
2 LOH- TGT T2 NO
3 L Codon175:CGC(Arg)-CTC(Leu) T T2 N2 III
4 LOH-I T2 NO
5 L Codon 155: ACC(Thr) GCC(Ala) - Ti Ni 1I
6 LOH - Ti NO I
7 LOH - T2 NO I
8 - Ti Ni II
9 - T2 NO I
10 - Codon249:AGG(Arg)-AGT(Ser) TGT T3 N2 III
ii - T2 NOI
12 -T2 NOI
123 Codon171:GAG(Glu) -GGAG(frameshiftinserion) G T2 N2 III
14 LOH- GTT T2 NOI
15 LOH T2 NOI
16 LOOH Codon 214: CAT (His) - CGT (Arg) - Ti NO
17 LOH - T2 NilIt
18 - - T2 N2 I
19 LOH T2 NO
20 LOH - T3 N2
21 LOH - T2 NO I
252_ - TGT T2 NO I
23 LOH - GTT T2 NO
24 Codon 26: GTG (Val) TTG (Leu) Ti NO
25 - GAT Ti NO
26 - TGT T2 Ni 11
27 LOH GTT T2 NO
28 - TGT Ti NO
29 LOtH-I T2 NilI
30 ~~LOH-I TGT T2 NO
31 LOH-I TGT T2 NO
32 LOH- Codon245:GGC(Gty)-*TGC(Cys) T2 N2 III
33 LOH GGT T2 NO
34 -Codon204:GAG(Glu)- TAG(stop) T2 NO
35 LOH- T2 NOI
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Figue 1 Microsatelite analyss of 35 king tumours developedi subjects who had never smoked and 35 adenocarcomas from heavy smokers with three
polmorpt markers (D3S1234, D3S1300, D3S4103ional to the FHIT gene. CD, Heterozygous; _, LOH; t, not inkxrnraive
(Li et aL 1994) and not significantly different from that observed in
the present series of lung tumours fim non-smoking subjects.
However, in the group of smokdng subjects, we found mostly
G:C-T:A transversions, whereas fiameshift mutations and
G:C-*AT transitions were more requendy seen in umours firom
non-smoking subjects. These data in keeping with results obtined
on smalle seriesofumous fromnon-smoking subjects, suggest that
endogenous mutational mechanisms, such as DNA polymeras infi-
delity, dnination of 5-methylcytosine and spontaneous depuina-
tion could play a funamental role in hmg carcogenesis in
non-smoking subjects. The firquency and type of codon 12 K-ras
mutations in the group of adenocarinomas from paients with a
history ofsmoking was similar tothatpreviously reported intheliter-
atire (Rodenhuis and Slebos, 1988; Slebos et aL 1991) and signifi-
cantly different from that observed in tumours from non-smoking
subjects. In conclusion, our data confirm that mutations of the p53
and K-ras genes and LOH at the FHIT locus are associated with
tobacco smoking; in addition, they indicate that the distribution of
such genetic abnormalities in adenocareinomas from non-smoking
subjectsisdifferent k-ras mutations are rare events, whereasp53 and
FHIT loci are concomitantly altered in 20% ofcases.
The constantassociation ofLOH at 3pl4.2 andp53 abnormalities
in tumours from non-smoking subjects is intriguing. Anamnestical
data were carefully collected; therefore, in the non-smoking
subjects' goup we canexclude ahistoryofsmoking, evenlimited to
a small number of cigarettes for few years. However, in 75% of
cases an exposition to environmental tobacco smoke was docu-
mented (Table 1). A number ofconsiderations let us conclude that
the observed associat ofp53 gene abnomalities and LOH at the
FH1T locus isindependent from the effect ofenvironmental tobacco
smoking: (a) no significant association was present between the
exposure of the patient to environmental smoking and these two
genetic changes; (b) in the group of patients with a history of
smoking, the fiequency of cases with concomitant alteration ofthe
FH1Tlocus andp53 gene was significantly lowerthan thatobserved
in non-smoking subjects; (c) p53 alterations in tumours from non-
smoking subjects were mostly G:C-*A:T transitions and deletions;
(d) no mutations ofthe K-ras gene at codon 12, which is known to
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be a specific target ofthe mutagenic activity oftobacco smoke. were
found in tumours showing FHIT and p53 abnormalities.
Alterations of a gene(s) involved in DNA mismatch repair could
lead to genetic instability and explain the concomitant presence of
gene defects (Aaltonen et aL 1993). As we did not find a microsatel-
lite instability outside ofthe FH1T locus in tmours with FHIT dele-
tions, the observed association ofp53 and FHIT aberrations does not
seem to be ascribable to mismatch repair gene deficiency leading to
replication errors (RERs). Anotherpossibility is that abnonnalities in
the p53 gene itself may destabilize the genome, favouring the pres-
ence ofmultiplegenetic anomalies (Livingstone etal. 1992; Y'm etaL
1992). In keeping with thishypothesis, it has been recently observed
that 3pl4 deletions are more frequent in cervical carcinomas associ-
atedwithpapillomavirus infection andp53 inactivation (Boldog etal,
1997). On the otherhand. p53 mutations appearuncommon in RER+
colorectal carcinomas and gastric tmours (Wu et al, 1994: Renault
et al. 1996). In the lightofthese observations, ourresults suggest that
in tumours from non-smoking subjects LOH at the FHIT locus are
not a consequence ofmismatch repairdeficiency, but may be related
with the genomic instability that accompanies p53 mutations.
However, a concomitant association of 3pl4.2 deletions and p53
gene abnormalities was notfrequent in tumours fromheavy smoking
subjects, indicating that this association is not a constant event in
human cancer. Inparticular, intunours from smokingsubjects, FHIT
gene alterations may be pimarily related to carinogens present im
tobacco smoke and not aconsequence ofp53 inactivation.
In the series of smoking patients p53 mutations were signifi-
cantly associated with metastatic involvement ofhilar/mediastinal
lymph nodes and advanced stages of disease, in agreement with
previous results (Marchetti et al, 1993; Lee et al, 1994). In non-
smoking subjects a trend towards these associations was observed.
but the data did not reach statistically significant values.
In conclusion, our results indicate that lung tumours developed
in never-smoking subjects represent a distinct biological entity in
which LOH at the FHIT locus and p53 mutations are concomi-
tantly present in 20% ofcases. On the contrary, this association of
molecular events was uncommon in tumours from heavy-smoking
subjects. As different p53 mutations were observed in these two
groups of lung tumours. we are tempted to hypothesize that LOH
at the FHIT locus in never-smoking subjects' lung cancer may be
dependent from the particular type of p53 mutations (G:C-*A:T
transitions and deletions). At this point it should be interesting to
evaluate the status of FHIT and p53 in other forms of human
malignancies in order to assess whether the association ofgenetic
abnormalities observed is restricted to lung cancer in non-smoking
subjects or common to other forms ofhuman neoplasms.
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